Valneva (NASDAQ:VALN) Trading 13.1% Higher - Should You Buy?

Valneva SE Sponsored ADR (NASDAQ:VALN - Get Free Report)'s share price traded up 13.1% on Wednesday . The company traded as high as $6.99 and last traded at $7.05. 16,281 shares traded hands during trading, a decline of 62% from the average session volume of 43,037 shares. The stock had previously closed at $6.23.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. HC Wainwright reaffirmed a "buy" rating and set a $17.00 target price on shares of Valneva in a report on Tuesday, April 15th. Guggenheim decreased their target price on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, May 8th.

Valneva Stock Up 1.2%

The stock's fifty day moving average price is $6.16 and its 200 day moving average price is $6.35. The stock has a market cap of $653.49 million, a P/E ratio of -6.45 and a beta of 1.74. The company has a current ratio of 2.70, a quick ratio of 2.12 and a debt-to-equity ratio of 0.92.

Valneva (NASDAQ:VALN - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) EPS for the quarter, topping analysts' consensus estimates of ($0.40) by $0.27. The firm had revenue of $51.79 million for the quarter, compared to analyst estimates of $41.80 million. Valneva had a negative net margin of 43.08% and a negative return on equity of 43.05%. As a group, research analysts forecast that Valneva SE Sponsored ADR will post 0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Valneva

An institutional investor recently bought a new position in Valneva stock. GAMMA Investing LLC purchased a new stake in shares of Valneva SE Sponsored ADR (NASDAQ:VALN - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 13,964 shares of the company's stock, valued at approximately $94,000. 11.39% of the stock is currently owned by institutional investors and hedge funds.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.